Myovant Executive Committee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
Myovant Sciences, Inc.April 5, 2021 GMT
BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with expertise in building and leading commercial teams accompanied by a record of successful product launches. She most recently served as Vice President, Neurological Rare Diseases at Genentech. Ms. Merendino will be a member of Myovant’s Executive Committee, reporting directly to Chief Executive Officer David Marek. ....

David Marek , Albert Liao , Adele Gulfo , Bryan Crowe , Myovant Sciences , Myovant Sciences Inc , Corporate Communications , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Myovant Executive Committee , Lauren Merendino , Chief Commercial Officer , Vice President , Neurological Rare Diseases , Executive Committee , Chief Executive Officer David , Sumitovant Biopharma , Investor Relations , டேவிட் மரேக் , ஆல்பர்ட் லியாவோ , ரியான் காகம் , பெருநிறுவன தகவல்தொடர்புகள் , தலைமை வணிகரீதியானது அதிகாரி , துணை ப்ரெஸிடெஂட் , நரம்பியல் ரேர் நோய்கள் , நிர்வாகி குழு ,